Efficacy and Safety of Vascana® in Subjects With Secondary Raynaud's Phenomenon

NCT02688270 | Completed Phase 2 Results

• 1 other identifier: VAS-014-001
• Study Type: interventional
• Target: 65
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to determine the ability of Vascana (0.9% nitroglycerin topical cream) to treat and prevent the symptoms experienced by subject's with Raynaud's Phenomenon. The symptoms of this disease include pain, tingling, and numbness in the fingers of the affected hand or hands.

Conditions

Raynaud's Phenomenon Secondary to Connective Tissue Disease

Outcome Measures

Primary Outcomes (2)

• Raynaud's Symptom Severity (Change From Baseline)

  Change from baseline to visit 6 in peak Main Raynaud's Symptom (MRS) severity. Raynaud's symptoms will be assessed separately using a 0 to100-mm Visual Analog Scale (VAS) for pain, numbness, and tingling where 0 mm = no symptom and 100 mm = most severe symptom.

  6 weeks

• Raynaud's Symptom Severity (Percentage of Responders)

  6 weeks

Study Arms (4)

Treatment Sequence A

EXPERIMENTAL

Vascana® (0.9% nitroglycerin cream), Vehicle cream, Vascana® (0.9% nitroglycerin cream), Vehicle cream

Drug: Vascana (0.9% nitroglycerin cream); Drug: Vehicle Cream (placebo)

Treatment Sequence B

EXPERIMENTAL

Vascana® (0.9% nitroglycerin cream), Vehicle cream, Vehicle cream, Vascana® (0.9% nitroglycerin cream)

Drug: Vascana (0.9% nitroglycerin cream); Drug: Vehicle Cream (placebo)

Treatment Sequence C

EXPERIMENTAL

Vehicle cream, Vascana® (0.9% nitroglycerin cream), Vehicle cream, Vascana® (0.9% nitroglycerin cream)

Drug: Vascana (0.9% nitroglycerin cream); Drug: Vehicle Cream (placebo)

Treatment Sequence D

EXPERIMENTAL

Vehicle cream, Vascana® (0.9% nitroglycerin cream), Vascana® (0.9% nitroglycerin cream), Vehicle cream

Drug: Vascana (0.9% nitroglycerin cream); Drug: Vehicle Cream (placebo)

Interventions

Vascana (0.9% nitroglycerin cream) DRUG

Study drug administered topically

Treatment Sequence A; Treatment Sequence B; Treatment Sequence C; Treatment Sequence D

Vehicle Cream (placebo) DRUG

Vehicle administered topically

Treatment Sequence A; Treatment Sequence B; Treatment Sequence C; Treatment Sequence D

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Provide written consent prior to any study-specific evaluation
• Males and females aged 18 years to 75 years, inclusive
• A clinical diagnosis of secondary Raynaud's Phenomenon (defined as Raynaud's Phenomenon (RP) significant enough to cause a patient to modify daily behavior) as determined by a history of cold sensitivity with pain, numbness, and/or tingling along with pallor or cyanosis of the fingers, or by such an event observed by the study physician and a diagnosis of a disease state known to be associated with RP. Secondary RP may be due to scleroderma, systemic lupus erythematosus, mixed connective tissue disease, or other connective tissue diseases
• Agree to apply the study drug to their fingers as specified in the protocol
• Agree to the controlled cold exposures as described in the protocol
• Willing to discontinue current vasodilator therapies used specifically for the treatment of Raynaud's
• Agree not to use any other investigational medications or approved or unapproved therapies to treat RP and its symptoms while participating in this study. Such medications include, but are not limited to: other dosages forms of nitroglycerin, eg, isosorbide dinitrate, fenoldopam mesylate, milrinone lactate, nifedipine, diltiazem, felodipine, nimodipine, nisoldipine, fluoxetine, pregabalin, and verapamil. Use of phosphodiesterase 5 inhibitors (eg, sildenafil, tadalafil, vardenafil) is excluded unless being used intermittently for male erectile dysfunction and not taken within 48 hours of scheduled study drug dosing
• Negative urine pregnancy test for women of child-bearing potential prior to the first study treatment and who agree to use effective contraception throughout the study
• Able to comply with all study requirements

You may not qualify if:

• Past history of RP attacks of sufficient severity as to require inpatient hospitalization
• Raynaud's Phenomenon secondary to non-connective tissue disorders including thromboangiitis obliterans (Buerger's disease), hemorheologic disorders, major arterial occlusive disease, past exposure to vasopathic agents (including vinblastine, cis platinum, and bleomycin), ongoing therapy with vasoconstrictive agents (eg, beta-blockers), and past frostbite injury amongst others. Subjects with hepatitis C should also be excluded.
• Patients diagnosed with pulmonary arterial hypertension requiring specific therapy.
• Concurrently using any nitrate medication or medications known to interact with nitroglycerin such as sildenafil, and other treatments for erectile dysfunction beyond screening. Subjects may participate in the study once these drugs have been discontinued for at least 5 half-lives
• Concurrently using any medication or device which might interfere with the study medication (including RP therapies, drugs used for hypertension, arrhythmia, depression, and pain), specifically calcium channel blockers and the compounds listed in prohibited concomitant medications beyond screening, unless such medication is required for a condition other than Raynaud's. Subjects may participate in the study once these drugs have been discontinued for at least 5 half-lives.
• Known allergy to nitroglycerin or common topical cream ingredients
• History of migraine, cluster, or vascular headaches, or chronic pain (defined as pain of 3-hour duration or longer on a daily basis) with greater intensity than the pain associated with RP or other chronic pain condition in their fingers
• Any unstable medical problem or any current medical condition that, in the judgment of the investigator, would contraindicate the administration of the study medication, interfere with the study evaluations, or interfere with the subject's ability to comply with the study protocol
• Cognitive or language difficulties that would impair completion of the symptom assessment instruments
• Within the past 3 months, have had a myocardial infarction, uncontrolled congestive heart failure, unstable angina, uncontrolled hypotension, or uncontrolled hypertension (defined as subjects not being treated medically to control these conditions)
• Participated in a study of any investigational drug within 4 weeks prior to visit 1
• Screening laboratory values are 20% or more from the upper or lower limit of normal and that are considered to be clinically significant to the investigator
• Had major abdominal, thoracic, or vascular surgery within 6 months of visit 1
• Pregnant or nursing women
• Women of childbearing potential who are unable or unwilling to comply with the contraceptive requirements during the study period

Sponsors & Collaborators

• Covis Pharma S.à.r.l.: lead

Study Sites (1)

Multiple investigational sites

Multiple Locations, Pennsylvania, United States

Location

Results Point of Contact

• Title: Clinical Trial Interest
• Organization: Covis Pharma

CTInterest@covispharma.com

18773744177

Publication Agreements

• PI is Sponsor Employee: No
• Restrictive Agreement: No

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 18, 2016
• First Posted: February 23, 2016
• Study Start: June 1, 2016
• Primary Completion: December 1, 2016
• Study Completion: December 1, 2016
• Last Updated: November 2, 2022
• Results First Posted: November 2, 2022

Record last verified: 2022-10

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)